Arbutus Biopharma Corp (ABUS) Operating income 2016–2025
Arbutus Biopharma Corp (ABUS) annual operating income history from SEC filings — each fiscal year as reported.
-$38.2MFY2025 · since FY2016: -$491.6M → -$38.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$38.2M | +50.0% |
| FY2024 | -$76.3M | +2.3% |
| FY2023 | -$78.1M | -19.3% |
| FY2022 | -$65.5M | +11.0% |
| FY2021 | -$73.5M | -27.2% |
| FY2020 | -$57.8M | +59.8% |
| FY2019 | -$143.9M | -60.3% |
| FY2018 | -$89.8M | +19.1% |
| FY2017 | -$110.9M | +77.4% |
| FY2016 | -$491.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ABUS financial trends
ABUS RevenueABUS Net incomeABUS Net marginABUS Gross profitABUS Gross marginABUS Operating marginABUS Operating cash flowABUS Free cash flowABUS Capital expendituresABUS Return on equityABUS Stock buybacksABUS Dividends paidABUS Total assetsABUS Total liabilitiesABUS Shareholders’ equityABUS overview →